|
gptkbp:instanceOf
|
gptkb:drug
gptkb:antidiabetic_medication
gptkb:DPP-4_inhibitor
|
|
gptkbp:approvalYear
|
2006
|
|
gptkbp:approvedBy
|
gptkb:United_States
|
|
gptkbp:ATCCode
|
A10BH01
|
|
gptkbp:brand
|
gptkb:Januvia
|
|
gptkbp:CASNumber
|
gptkb:486460-32-6
|
|
gptkbp:chemicalFormula
|
C16H15F6N5O
|
|
gptkbp:combines
|
gptkb:metformin
gptkb:phentermine
gptkb:ertugliflozin
gptkb:simvastatin
|
|
gptkbp:contraindication
|
gptkb:diabetic_ketoacidosis
type 1 diabetes
|
|
gptkbp:developer
|
gptkb:Merck_&_Co.
|
|
gptkbp:effect
|
weight neutral
reduces blood glucose
lowers HbA1c
|
|
gptkbp:eliminationHalfLife
|
12.4 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:improves
|
glycemic control
incretin levels
|
|
gptkbp:KEGGID
|
D06402
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits DPP-4 enzyme
|
|
gptkbp:metabolism
|
minimal
|
|
gptkbp:molecularWeight
|
407.31 g/mol
|
|
gptkbp:notRecommendedFor
|
severe renal impairment
end-stage renal disease
|
|
gptkbp:patentExpired
|
2022 (US)
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:prescribes
|
adults
children (in some countries)
|
|
gptkbp:PubChem_CID
|
gptkb:DB01261
gptkb:CHEMBL573
4369359
|
|
gptkbp:riskFactor
|
pancreatitis
hypoglycemia (when combined with sulfonylureas)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:bullous_pemphigoid
headache
joint pain
allergic reactions
upper respiratory tract infection
nasopharyngitis
|
|
gptkbp:UNII
|
X4W7ZR7023
|
|
gptkbp:usedFor
|
gptkb:type_2_diabetes_mellitus
|
|
gptkbp:bfsParent
|
gptkb:Januvia
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
sitagliptin
|